Archives of Neuroscience

Published by: Kowsar

Fingolimod for Multiple Sclerosis; Mechanism of Action, Safety and Toxicity

Zahra Tolou-Ghamari 1 , * and Hamid Mazdak 2
Authors Information
1 Isfahan Kidney Transplantation Research Center, Alzahra Research Institutes, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Department of Urology, Alzahra Hospital, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Archives of Neuroscience: July 01, 2016, 3 (3); e31295
  • Published Online: June 5, 2016
  • Article Type: Review Article
  • Received: July 5, 2015
  • Revised: December 20, 2015
  • Accepted: January 10, 2016
  • DOI: 10.5812/archneurosci.31295

To Cite: Tolou-Ghamari Z, Mazdak H. Fingolimod for Multiple Sclerosis; Mechanism of Action, Safety and Toxicity, Arch Neurosci. 2016 ; 3(3):e31295. doi: 10.5812/archneurosci.31295.

Copyright © 2016, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Ross AP, Ben-Zacharia A, Harris C, Smrtka J. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol. 2013; 4: 21[DOI][PubMed]
  • 2. Tolou-Ghamari Z. Demographic analysis of patients with multiple sclerosis; individual variability related to the time interval. Arch Neurosci. 2015; 2(3)[DOI]
  • 3. Tolou-Ghamari Z. Scattering month and day of baby delivery in a retrospective survey linked to 1484 patients with multiple sclerosis. Arch Neurosci. 2015; 2(3)[DOI]
  • 4. Tolou-Ghamari Z. A review of geoepidemiological differences of multiple sclerosis in iran and other middle east countries. Arch Neurosci. 2014; 2(3)[DOI]
  • 5. Tolou-Ghamari Z, Shaygannejad V, Ashtari F. Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital. Int J Prev Med. 2013; 4-8[PubMed]
  • 6. Derfuss T, Bergvall NK, Sfikas N, Tomic DL. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2015; 31(9): 1687-91[DOI][PubMed]
  • 7. Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry. 2005; 76(2): 206-11[DOI][PubMed]
  • 8. Frohman EM, Eagar T, Monson N, Stuve O, Karandikar N. Immunologic mechanisms of multiple sclerosis. Neuroimaging Clin N Am. 2008; 18(4): 577-88[DOI][PubMed]
  • 9. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol. 2005; 62(9): 1345-56[DOI][PubMed]
  • 10. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006; 354(9): 942-55[DOI][PubMed]
  • 11. Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity. 2003; 36(3): 133-41[PubMed]
  • 12. Pierson ER, Stromnes IM, Goverman JM. B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system. J Immunol. 2014; 192(3): 929-39[DOI][PubMed]
  • 13. Dumont FJ. Fingolimod. Mitsubishi Pharma/Novartis. IDrugs. 2005; 8(3): 236-53[PubMed]
  • 14. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005; 108(3): 308-19[DOI][PubMed]
  • 15. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos. 2006; 34(9): 1480-7[DOI][PubMed]
  • 16. Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood. 2007; 109(3): 1077-85[DOI][PubMed]
  • 17. Kremenchutzky M, O'Connor P, Hohlfeld R, Zhang-Auberson L, von Rosenstiel P, Meng X, et al. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Mult Scler Relat Disord. 2014; 3(3): 341-9[DOI][PubMed]
  • 18. Fragoso YD, Alves-Leon SV, Barreira AA, Callegaro D, Brito Ferreira ML, Finkelsztejn A, et al. Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years. Pediatr Neurol. 2015; 53(2): 166-8[DOI][PubMed]
  • 19. Thomas RH, Wakefield RA. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Am J Health Syst Pharm. 2015; 72(1): 25-38[DOI][PubMed]
  • 20. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355(11): 1124-40[DOI][PubMed]
  • 21. Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH, et al. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol. 2007; 170(1): 281-92[DOI][PubMed]
  • 22. Martini S, Peters H, Bohler T, Budde K. Current perspectives on FTY720. Expert Opin Investig Drugs. 2007; 16(4): 505-18[DOI][PubMed]
  • 23. Baumruker T, Billich A, Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs. 2007; 16(3): 283-9[DOI][PubMed]
  • 24. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016; 87(5): 468-75[DOI][PubMed]
  • 25. Endo H, Chihara N, Sekiguchi MDK, Kowa H, Kanda F, Toda T. [A case of multiple sclerosis who relapsed early after fingolimod therapy introduced]. Rinsho Shinkeigaku. 2015; 55(6): 417-20[DOI][PubMed]
  • 26. Ziemssen T, Kern R, Cornelissen C. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol. 2015; 15: 93[DOI][PubMed]
  • 27. Anlar O. Treatment of multiple sclerosis. CNS Neurol Disord Drug Targets. 2009; 8(3): 167-74[PubMed]
  • 28. Lee JM, Han MH. Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod. Patient Prefer Adherence. 2015; 9: 685-93[DOI][PubMed]
  • 29. Racca V, Di Rienzo M, Cavarretta R, Toccafondi A, Vaini E, Ferratini M, et al. Fingolimod effects on left ventricular function in multiple sclerosis. Mult Scler. 2016; 22(2): 201-11[DOI][PubMed]
  • 30. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 402-15[DOI][PubMed]
  • 31. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007; 323(2): 469-75[DOI][PubMed]
  • 32. Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009; 19(2): 254-66[DOI][PubMed]
  • 33. Nishihara H, Shimizu F, Sano Y, Takeshita Y, Maeda T, Abe M, et al. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. PLoS One. 2015; 10(3): 121488[DOI][PubMed]
  • 34. Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015; 84(16): 1639-43[DOI][PubMed]
  • 35. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 387-401[DOI][PubMed]
  • 36. Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013; 120(7): 1432-9[DOI][PubMed]
  • 37. Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2015; 29(3): 207-20[DOI][PubMed]
  • 38. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007; 323(2): 469-75[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments